With all the complexity of the problems raised by patients with AD, there are currently only two established categories of pharmaceutical drugs approved by the FDA for the symptomatic therapy of this formidable pathology; these include cholinesterase inhibitors (naturally derived analogues, synthetics and hybrids) and NMDAR competitors. This evidence concerns the gene BCHE and Alzheimer disease.